Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Suspended × Brentuximab Vedotin × Clear all

Phase

Status

Completed 10 Withdrawn 3 Terminated 2 Unknown 1 Suspended 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Drug Therapy 3 pembrolizumab 2 Vincristine 2 Temozolomide 2 S 1 (combination) 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Gemcitabine 2 Cyclophosphamide 2 Carboplatin 2 CA-4948 2 Bevacizumab 2 zimberelimab 1 venetoclax 1 tivozanib 1 titanium silicide 1 tisagenlecleucel 1 sotigalimab 1 selinexor 1 prednylidene 1 pimonidazole 1 palbociclib 1 imisopasem manganese 1 iberdomide 1 gusacitinib 1 gallium 68 PSMA-11 1 fludarabine 1 deltacortene 1 cabazitaxel 1 brincidofovir 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03187210 2025-03-30

BAL

Insel Gruppe AG, University Hospital Bern

Phase 1/2 Suspended

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡